Chris Gibson
Co-Founder & CEO @ Recursion Pharmaceuticals
Salt Lake City, United States
Chris Gibson is a Series A investor at Recursion Pharmaceuticals in Salt Lake City focused on Biotechnology and Health Care. Chris Gibson is the Co-Founder and CEO of Recursion (Recursion Pharmaceuticals). He previously worked at Cure HHT as a Member Board of Directors. Chris Gibson attended the University of Utah.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Chris Gibson invests in
Stages Chris Gibson invests in
Countries Chris Gibson invests in
Round sizes
Round size
- Seed
- $4.9M–$14M
- Series A
- $6.3M–$55M
Investment Focus
Industry
- Biotechnology 6 (60%)
- Health Care 4 (40%)
- Life Science 3 (30%)
- Pharmaceutical 3 (30%)
- Machine Learning 3 (30%)
Stage
- Series A 6 (60%)
- Seed 4 (40%)
Country
- United States 6 (60%)
- France 1 (10%)
- Switzerland 1 (10%)
- United Kingdom 1 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Leash Biosciences
|
Leash Biosciences engages in machine learning to solve medicinal chemistry. | $9.3M / Seed / Apr 05, 2024 | |
Cradle
|
Using robust prediction algorithms and AI design recommendations, Cradle assists biologists in rapidly designing better proteins. Cradle gives you complete ownership of the intellectual property while maintaining the privacy and security of your sequences and data. | $24M / Series A / Nov 28, 2023 | |
Amenities Health
|
Amenities is the healthcare industry's leading Digital Front Door and patient loyalty platform. We help healthcare providers to acquire new patients and upgrade them to members. Our all-in-one patient app works with most modern EMRs to: 1) register new users into a full EMR account in <30 seconds with full identity verification and noduplicates, 2) help those patients find care options and book appointments with simple, conversion-optimized workflows, 3) seamlessly integrates key patient portal and 3rd party functions (i.e., video visits, secure messaging, test results, and billing), and 4) upgrade patients to members with custom experiences and services offerings (i.e., for Medicare Advantage, concierge memberships, direct-to-employer, or direct primary care patients) | $6.3M / Series A / Sep 19, 2023 | |
Noetik
|
Noetik is an AI-native biotechnology company. Noetik leverages in advanced machine learning methods to discover and develop cancer immunotherapies. | $14M / Seed / Sep 07, 2023 | |
64x Bio
|
A comprehensive platform and product suite for advanced therapeutics. | $55M / Series A / Jan 19, 2022 | |
Known Medicine
|
Known Medicine is looking to take the experimentation of how tumors respond to cancer drugs out of the patient’s body and into the lab. The startup breaks down tumor samples into micro tumors, which they treat separately inside specialized micro-environments with different methods and see what works best. | $7.2M / Seed / Aug 25, 2021 | |
Enveda Biosciences
|
Enveda Biosciences is a biotechnology company building new medicines from plants. It harnesses the complexity of the natural world to tackle today’s biggest healthcare challenges. With the help of the advancements in knowledge graphs, machine learning, and metabolomics, they discover the next generation of small molecules. Its technologiessystematize the discovery of small molecules and novel targets for complex diseases. By probing novel chemical space and mechanisms of action, they are breaking the status quo for challenging diseases with a need for effective treatments, such as fibrosis or neurodegeneration.Enveda, launched in 2019, is based in San Francisco, California. | $51M / Series A / Jun 22, 2021 | |
|
Enveda Biosciences
|
Enveda Biosciences is a biotechnology company building new medicines from plants. It harnesses the complexity of the natural world to tackle today’s biggest healthcare challenges. With the help of the advancements in knowledge graphs, machine learning, and metabolomics, they discover the next generation of small molecules. Its technologiessystematize the discovery of small molecules and novel targets for complex diseases. By probing novel chemical space and mechanisms of action, they are breaking the status quo for challenging diseases with a need for effective treatments, such as fibrosis or neurodegeneration.Enveda, launched in 2019, is based in San Francisco, California. | $4.9M / Seed / Aug 11, 2020 | |
Inato
|
Inato automates data structuring and analysis, cross-checks data sources, and provides insights on this data. It features a tool for collecting and analyzing data used in clinical trials, Inato’s AI-powered platform enables pharmaceutical companies to drastically reduce drug development costs. By accelerating clinical trials, Inato helps newtherapies arrive to patients faster, and at lower prices | $14M / Series A / Feb 04, 2020 | |
LabGenius
|
LabGenius is a biopharmaceutical company developing protein therapeutics using a machine learning-driven evolution engine. Its protein engineering platform integrates several bleeding-edge technologies from the fields of machine learning, synthetic biology, and robotics. | $10M / Series A / Oct 22, 2019 |
Co-Investors
About Recursion Pharmaceuticals
Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Central to our mission is the Recursion Operating System, or Recursion OS,that combines an advanced infrastructure layer to generate what we believe is one of the world's largest and fastest-growing proprietary biological and chemical datasets and the Recursion Map, a suite of custom software, algorithms, and machine learning tools that we use to explore foundational biology unconstrained by human bias and navigate to new biological insights which may accelerate our programs. We are a biotechnology company scaling more like a technology company.
Recursion Pharmaceuticals Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Chris Gibson
Co-Founder & CEO
|
|||
Michael Secora
Chief Financial Officer
|
|||
Ben Mabey
CTO
|
|||
Blake Borgeson
Co-founder, Board Member
|
|||
Christopher Gibson
Interim Executive Advisor
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Chris Gibson invest in?
Chris Gibson invests primarily in Biotechnology, Health Care and Life Science startups, most often at Series A and Seed stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Chris Gibson's check size?
Chris Gibson typically joins rounds of $4.9M–$14M at Seed and $6.3M–$55M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Chris Gibson participates in.
When did Chris Gibson last invest?
The most recent investment recorded for Chris Gibson closed in Apr 2024. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
